2015
DOI: 10.1007/s00198-015-3347-z
|View full text |Cite
|
Sign up to set email alerts
|

Denosumab after 8 years

Abstract: It is now more than 20 years since the alendronate phase 3 program produced the first trials demonstrating global antifracture efficacy for an osteoporosis medication [1,2]. This brought the osteoporosis field into the era of evidence-based medicine. The euphoria that followed from knowing that the interventions we were prescribing really were preventing fractures soon passed as durations of therapy reached 3 years, the endpoint of most fracture prevention clinical trials. A series of unanswered questions then… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2016
2016
2019
2019

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 20 publications
0
1
0
Order By: Relevance
“…158160 Because the current evidence suggest that osteocytes are one of the sources of RANKL and OPG in bone, therapeutic approaches modulating this pathway are examples of the potential benefits of targeting osteocytes to improve skeletal health.…”
Section: Osteocytic Signaling Pathways As Therapeutic Targetsmentioning
confidence: 99%
“…158160 Because the current evidence suggest that osteocytes are one of the sources of RANKL and OPG in bone, therapeutic approaches modulating this pathway are examples of the potential benefits of targeting osteocytes to improve skeletal health.…”
Section: Osteocytic Signaling Pathways As Therapeutic Targetsmentioning
confidence: 99%